

## DOCUMENT MADE AVAILABLE UNDER THE PATENT COOPERATION TREATY (PCT)

International application number:	<b>PCT/IB2018/055968</b>
International filing date:	<b>08 August 2018 (08.08.2018)</b>
Document type:	<b>Certified copy of priority document</b>
Document details:	Country/Office: <b>IN</b>
	Number: <b>201741028199</b>
	Filing date: <b>08 August 2017 (08.08.2017)</b>
Date of receipt at the International Bureau:	<b>17 December 2018 (17.12.2018)</b>

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-bis)

IB18/55968



**INTELLECTUAL  
PROPERTY INDIA**

पेटेंट|डिजाइन| व्यापार  
चिह्न|भौगोलिक उपदर्शन



सत्यमेव जयते

**भारत सरकार**  
**GOVERNMENT OF INDIA**  
**वाणिज्य एवं उद्योग मंत्रालय**  
**MINISTRY OF COMMERCE & INDUSTRY**  
**पेटेंट कार्यालय**  
**THE PATENT OFFICE**

**जिस किसी से संबन्धित हो**  
**TO WHOMSOEVER IT MAY CONCERN**

में, अधोहस्ताक्षरी जो पेटेंट अधिनियम, 1970 की धारा 73(3) के तहत महानियंत्रक एकस्व, अभिकल्प एवं व्यापार चिह्न की ओर से प्रमाणपत्र हस्ताक्षर व जारी करने के लिए प्राधिकृत अधिकारी हूँ, एतद्वारा यह प्रमाणित करता(ती) हूँ कि निम्नलिखित पेटेंट आवेदन के संबंध में फाइल दस्तावेज़(जों) की सही प्रतिलिपि इसके साथ संलग्न है:

I, the undersigned, being an officer duly authorized to sign and issue the certificate on behalf of the Controller General of Patents, Designs and Trademarks in accordance with the provisions of Section 73(3) of the Patents Act, 1970, hereby certify that annexed hereto is a True Copy of the document(s) as filed in connection with the following Patent Application:

क) आवेदन संख्या/a) Application Number: 201741028199

ख) फाइल करने की तारीख/b) Date of Filing: 08/08/2017

ग) अनुरोधित दस्तावेज़(जों) का नाम:

C) Name of the document(s) requested: Provisional Specification

यह प्रमाणपत्र पेटेंट अधिनियम, 1970 की धारा 147(1) के अधीन मुझमें निहित शक्तियों के तहत जारी किया गया है। This certificate is issued under the powers vested in me U/S 147(1) of The Patents Act, 1970.

Dated this 5th day of November 2018

नियंत्रक पेटेंट व डिजाइन/Controller of Patents and Designs  
(प्राधिकृत हस्ताक्षरी/Authorised Signatory)

**FORM 2**

**THE PATENTS ACT 1970**

(39 of 1970)

&

The Patents Rules, 2003

**PROVISIONAL SPECIFICATION**

(See section 10 and rule 13)

**EXTRUDATE ENZALUTAMIDE COMPOSITIONS**

**Dr. Reddy's Laboratories Ltd.**

An Indian company having its registered office at

8-2-337, Road No. 3, Banjara hills,

Hyderabad – 500034,

Telangana, India

The following specification describes the invention

201741028199  
08/08/2017

## EXTRUDATE ENZALUTAMIDE COMPOSITIONS


### FIELD OF THE INVENTION

The present invention relates to novel oral extrudate pharmaceutical compositions of enzalutamide. Methods of preparing such compositions are also provided.

### BACKGROUND OF THE INVENTION

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other parts of the body, particularly the bones and lymph nodes. Prostate cancer is a common cancer in men, especially in the US and in Europe.

Enzalutamide is an androgen receptor signaling inhibitor. The chemical name is 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylide-neimidazolidin-1-yl}-2-fluoro-N-methylbenzamide. The structural formula is:



Enzalutamide is non-hygroscopic, crystalline solid that remain unionized over the physiologic pH range. It is poorly soluble; in particular sparingly soluble in absolute ethanol and practically insoluble in water between pH 1 and 11, soluble in acetone

and N-methyl-2-pyrrolidone (NMP). It is a Class II drug as per the biopharmaceutics classification system. Poor drug solubility however represents a bottleneck for dissolution, which in turn critically affects drug bioavailability.

Enzalutamide is marketed as XTANDI® and used for the treatment of castration-resistant prostate cancer. Enzalutamide also is reported for treating breast cancer, prostate cancer, benign prostate hyperplasia and ovarian cancer.

According to the FDA, XTANDI® is a liquid-filled soft gelatin capsule for oral administration comprising enzalutamide. The recommended dose of XTANDI® is 160 mg, which should be administered orally once daily in the form of four capsules each containing 40 mg of active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is dissolved in the caprylocaproyl polyoxylglycerides solvent (Labrasol®). The administration of XTANDI® is reported to be independent of food uptake. The patient should swallow the whole capsule which should not be chewed, dissolved or opened prior to swallowing.

A disadvantage of the recommended dose is taking four capsules daily (160 mg once daily). Further, these capsules are reported to be very large due to the great amount of Labrasol® necessary to keep the active pharmaceutical ingredient in solution. Due to its large size (capsule size 12) and the high number of capsules that has to be taken, this dosage form is difficult to swallow, in particular for older men, resulting in a poor patient compliance, especially in said important patient group.

Moreover, the above-mentioned composition comprising enzalutamide shows poor dissolution behaviour at acidic conditions, especially under simulated gastric fluid which appears to be incomplete. In particular, the API does not remain dissolved but seems to precipitate.

Thus, there remains a need to develop a stable pharmaceutical composition of enzalutamide with improved patient compliance by providing small dosage forms, in weight and in physical volume, in order to be easily swallowable by patients and come in a small number of units per daily recommended dose, preferably in single dosage unit. Further desirable object includes improved dissolution and bioavailability associated with the current dosage form.

US20140179749 discloses solid dispersion compositions of enzalutamide.

WO2015118015 discloses solid adsorbate or solid dispersion compositions of enzalutamide.

WO2015022349 discloses enzalutamide composition in first and second solvent and optionally an oil component, wherein the enzalutamide is present in a dissolved form.

In an attempt to develop novel oral improved enzalutamide compositions, the present inventors have surprisingly found that extrudate pharmaceutical compositions of enzalutamide with one or more suitable polymers prepared by using twin screw extrusion or hot melt extrusion resulted in chemically stable compositions having improved drug loading and improved patient compliance.

#### **SUMMARY OF THE INVENTION**

The present specification relates to novel oral extrudate pharmaceutical compositions of enzalutamide.

In one aspect, the present specification relates to an oral extrudate pharmaceutical composition comprising:

- (i) 160 mg or 80 mg enzalutamide; and
- (ii) one or more polymers.

In another aspect, the present specification relates to an oral extrudate pharmaceutical composition comprising:

- (i) enzalutamide,
- (ii) one or more polymers, and
- (iii) one or more pharmaceutically acceptable excipients.

In yet another aspect, the present specification relates to an oral extrudate pharmaceutical composition comprising:

- (i) enzalutamide,
- (ii) hydroxypropyl cellulose and or hydroxyethyl cellulose, and
- (iii) one or more pharmaceutically acceptable excipients.

In yet another aspect, the present specification relates to an oral extrudate pharmaceutical composition comprising:

- (i) enzalutamide,
- (ii) one or more non-cellulosic polymers, and
- (iii) one or more pharmaceutically acceptable excipients.

The pharmaceutical compositions of the present specification may be used for the treatment of prostate cancer, breast cancer, benign prostate hyperplasia and ovarian cancer.

#### **DESCRIPTION OF THE INVENTION**

The present specification relates to novel oral extrudate pharmaceutical compositions of enzalutamide.

In one aspect, the present specification relates to an oral extrudate pharmaceutical composition comprising:

- (i) 160 mg or 80 mg enzalutamide, and
- (ii) one or more polymers.

In another aspect, the present specification relates to an oral extrudate pharmaceutical composition comprising:

- (i) enzalutamide,
- (ii) one or more polymers, and
- (iii) one or more pharmaceutically acceptable excipients.

In yet another aspect, the present specification relates to an oral extrudate pharmaceutical composition comprising:

- (i) enzalutamide,
- (ii) hydroxypropyl cellulose and or hydroxyethyl cellulose, and
- (iii) one or more pharmaceutically acceptable excipients.

In yet another aspect, the present specification relates to an oral extrudate pharmaceutical composition comprising:

- (i) enzalutamide,
- (ii) one or more non-cellulosic polymers, and
- (iii) one or more pharmaceutically acceptable excipients.

As used herein, the term "oral pharmaceutical composition" refers to an oral dosage form comprising tablets, pills, sachets, or capsules. The preferred oral dosage form is in the form of capsule or tablet. The term "extrudate oral pharmaceutical composition" refers to the compositions prepared by twin screw extrusion or hot melt extrusion using a conventional extruder well known in the art.



The term "enzalutamide" refers to enzalutamide and esters, salts, or derivatives thereof. Enzalutamide could be crystalline or amorphous (i.e., in a non-crystalline state) forms as known in the prior art. Amorphous enzalutamide may be prepared by any known means, including spray-drying, hot melt extrusion, and precipitation from solution on addition of a non-solvent. Amorphous enzalutamide dissolves more quickly and to a greater extent than crystalline enzalutamide in an aqueous use environment, such as an aqueous dissolution medium of an in vitro dissolution test (e.g., phosphate buffered saline or model fasted duodenal fluid or simulated gastric fluid) or the in vivo environment of the stomach or small intestine. The amount of enzalutamide present in the extrudate compositions is about 10 to 250 mg, preferably from 20 to 160 mg.

Polymers suitable for use in the extrudate compositions of the present specification are inert, are pharmaceutically acceptable (i.e. are non-toxic), and have at least some solubility in aqueous solution at physiologically relevant pH (e.g. 1-10). The polymers may be cellulosic or non-cellulosic. The polymers may be neutral or ionizable in aqueous solution.

Exemplary neutral non-ionizable cellulosic polymers of the present specification include hydroxypropyl methyl cellulose acetate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, Hydroxyethyl methyl cellulose, Hydroxyethyl cellulose acetate, Hydroxyethyl ethyl cellulose and any mixtures thereof.

Exemplary cellulosic polymers that are at least partially ionized at physiologically relevant pH include: hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose succinate, hydroxypropyl cellulose acetate succinate, Hydroxyethyl methyl cellulose succinate, Hydroxyethyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, Hydroxyethyl methyl cellulose acetate

succinate, Hydroxyethyl methyl cellulose acetate phthalate and any mixtures thereof. A particularly desirable subset of cellulosic ionizable polymers are those that possess both a carboxylic acid functional aromatic substituent and an alkylate substituent and thus are amphiphilic.

In some embodiments, the polymers used in the present specification comprises neutral non-cellulosic polymers, including, but not limited to, vinyl polymers and copolymers having substituents of hydroxyl, alkylacyloxy, and cyclicamido polyvinyl alcohols that have at least a portion of their repeat units in the unhydrolyzed (vinyl acetate) form; polyvinyl alcohol polyvinyl acetate copolymers; polyvinyl pyrrolidone; polyvinylpyrrolidone vinyl acetate; and polyethylene polyvinyl alcohol copolymers.

Another class of polymers comprises ionizable non-cellulosic polymers, including, but not limited to, carboxylic acid-functionalized vinyl polymers, such as the carboxylic acid functionalized polymethacrylates and carboxylic acid functionalized polyacrylates such as the EUDRAGIT®.

Non-cellulosic polymers that are amphiphilic are copolymers of a relatively hydrophilic and a relatively hydrophobic monomer. Examples include acrylate and methacrylate copolymers. Commercial grades of such copolymers include the EUDRAGIT®, which are copolymers of methacrylates and acrylates; and graft copolymers of polyethylene glycol, polyvinylcaprolactam, and polyvinylacetate, one commercially available version of a graft copolymer known as SOLUPLUS®.

The extrudate oral pharmaceutical composition according to the present specification may further comprise one or more pharmaceutically acceptable excipients. Such excipients include fillers, disintegrants, binders, lubricants, glidants, film-forming agents and coating materials, sweeteners, flavoring agents, plasticizers, surfactants

and coloring agents such as pigments. Other excipients known in the field of pharmaceutical compositions may also be used.

Fillers or diluents, may be selected from the group consisting of different grades of starches, such as maize starch, potato starch, rice starch, wheat starch, Pregelatinised starch, fully Pregelatinised starch; cellulose derivatives, such as microcrystalline cellulose or silicified microcrystalline cellulose; sugar alcohols such as Mannitol, erythritol, sorbitol, xylitol; monosaccharides like glucose; oligosaccharides like sucrose and lactose such as lactose monohydrate, lactose anhydrous, spray dried lactose or anhydrous lactose; calcium salts, such as calcium hydrogenphosphate; particularly preferably the fillers are selected from the group consisting of, microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, spray dried lactose, and anhydrous lactose.

Suitable disintegrants may be selected from the group consisting of carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium (cellulose carboxymethylether sodium salt, crosslinked), starch, modified starch such as pregelatinized starch, starch derivatives such as sodium starch glycolate, crosslinked polyvinylpyrrolidone (crospovidone), and low-substituted hydroxypropylcellulose, and disintegrating aids such as magnesium alumino-metasilicate and ion exchange resins like polacrillin potassium; particularly preferably the disintegrants are selected from the group consisting of sodium starch glycolate, croscarmellose sodium and crospovidone.

Suitable binders may be selected from the group consisting of polyvinyl pyrrolidone (Povidone), polyvinyl alcohol, copolymers of vinylpyrrolidone with other vinyl derivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and pregelatinized starch.

Suitable lubricants may be selected from the group consisting of stearic acid, talc, glyceryl behenate, sodium stearyl fumarate and magnesium stearate; particularly preferably the lubricant is magnesium stearate and sodium stearyl fumarate.

Glidants, if used, may be selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicate, such as talc; particularly preferably the glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica.

Suitable film-forming agents and coating materials, if used, e.g. for the preparation of film coatings on API-containing tablets, may include, but are not limited to hydroxypropyl methylcellulose (Hypromellose), hydroxypropyl cellulose, polyvinylalcohol, methylcellulose, ethylcellulose, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, shellac, liquid glucose, hydroxyethyl cellulose, polyvinylpyrrolidone, copolymers of vinylpyrrolidone and vinylacetate such as Kollidon® VA64 BASF, copolymers of acrylic and/or methacrylic acid esters with trimethylammoniummethacrylate, copolymers of dimethylaminomethacrylic acid and neutral methacrylic acid esters, polymers of methacrylic acid or methacrylic acid esters, copolymers of acrylic acid ethylester and methacrylic acid methyl ester, and copolymers of acrylic acid and acrylic acid methylester.

Suitable sweeteners may be selected from the group consisting of aspartame, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin, and the like.

Plasticizers, if used, may include, but are not limited to polyethylene glycol, diethyl phthalate and glycerol. Preference is given to polyethylene glycol.

Suitable surfactants as component can be selected from the group consisting of anionic surfactants, preferably sodium lauryl sulphate; polyethylene glycols (PEGs), preferably those PEGs having molecular weight in the range of about 2000 to 10000, more preferably PEG 3350, PEG 4000, PEG 6000, PEG 8000; Polysorbates, preferably Tween 20, Tween 80 or Span 80; fatty acid esters, preferably propylene glycol caprylates such as Capmul PG-8, Capryol 90; esters of glycerol and fatty acids, preferably glycerol oleates and caprylates (Capmul MCM); esters of polyethylene glycol and fatty acids, such as Labrasol and Solutol; castor oil ethoxylate (glycerol polyethylene glycol ricinoleate) such as Cremophor EL and Cremophor RH 40. More preferably the surfactant is selected from the group consisting of sodium lauryl sulphate; PEG 3350, PEG 4000, PEG 600 or, PEG 8000 and preferably PEG 6000; Tween 20 or Tween 80; and esters of polyethylene glycol and fatty acids, most preferably sodium lauryl sulphate and PEG 6000 and in particular sodium lauryl sulphate.

The extrudate composition of the present specification may further include an antioxidant. The antioxidant may be selected from one or more of DL-alpha-tocopherol, butylhydroxy toluene (BHT), butylhydroxy anisole (BHA), ascorbyl palmitate, ascorbic acid and propyl gallate.

As suitable dosage forms, the extrudate pharmaceutical composition according to the present invention is in the form of a capsule or a tablet. For example, a capsule such as a gelatine capsule may be filed with extrudate formed through twin screw extrusion or hot melt extrusion or a tablet is compressed using such extrudate and other pharmaceutically acceptable excipients useful for such technologies and optionally further film-coated.

The extrudate pharmaceutical compositions of the present specification may be prepared by conventional twin screw or hot melt extrusion process for oral solid

dosage forms. For example, the extrudates may be prepared by using dry-powder blends of enzalutamide and polymer. Various drug and polymer ratio has been studied. Using a Gravimetric powder feeder, the blends are fed at a controlled rate to a twin screw extruder. The extruder has a temperature controller and is equipped with a cylindrical die. Extrudates are collected at the die end and milled in to different sizes for direct use or further processing accordingly. The milled extrudate can be mixed with suitable excipients and filled into a hard gelatin capsule or compressed in to a tablet and suitably packed in conventional blister pack or stick pack.

In some embodiments, the amount of enzalutamide present in the extrudate pharmaceutical compositions of the present specification is 80 mg or 160 mg. The final extrudate compositions when compressed in to tablets or filled in the capsule has a suitable size and thus reduce the number of administered units such that the patient compliance can be improved.

In some embodiments, enzalutamide present in the final extrudate pharmaceutical compositions is mainly in amorphous state, preferably substantially amorphous state. "Mainly" amorphous denotes "more than 50%", "substantially" amorphous denotes that at least 90 %, preferably 95 % or 97 %, more preferably all of the respective compound is amorphous. In other words, "amorphous" means minor amounts and preferably no substantial amounts, of crystalline portions of the respective compound, as e.g. measurable upon X-ray powder diffraction (XRPD) analysis.

The extrudate pharmaceutical composition according to the present specification is particularly useful in medical treatments, specifically in the treatment of prostate cancer and breast cancer, benign prostate hyperplasia and ovarian cancer and in particular in the treatment of male patients with metastatic castration-resistant prostate cancer.

The extrudate pharmaceutical compositions of the present specification would be subjected to in-vitro dissolution studies and accelerated and long term stability studies.

The oral pharmaceutical compositions of the present specification may be subjected to pharmaceutical bioequivalence testing in comparison with the reference product (XTANDI®) in an open-label, randomized, two-treatment, two-period, single-dose, crossover study in healthy adult human male subjects under fasting and fed conditions.

Some exemplary extrudate composition according to the present specification is given below.

Table 1: Formulation compositions

Example 1	Example 2	Example 3	Example 4	Example 5	Example 6
Enzalutamide HPMC-AS Hydroxypropyl cellulose Lactose Magnesium Stearate	Enzalutamide PLA-PVA-PEG graft polymer Hydroxyethyl cellulose Microcrystalline cellulose Croscarmellose sodium Magnesium Stearate	Enzalutamide Eudragit® L (100-55) Microcrystalline cellulose Croscarmellose sodium Magnesium Stearate	Enzalutamide CO-PVP Polyvinylpyrrolidone lactose Magnesium Stearate	Enzalutamide PVP-VA 64 Eudragit® L (100-55) Lactose Magnesium stearate	Enzalutamide PVP-VA 64 Eudragit® E 100 Lactose Magnesium stearate

Dated this 8<sup>th</sup> August, 2017

Signature: \_\_\_\_\_  
Dr. Poonam Raghuvanshi.

## ABSTRACT

The invention relates to novel oral extrudate pharmaceutical compositions of enzalutamide. The compositions comprise one or more suitable polymers and are prepared using twin screw extrusion or hot melt extrusion. Methods of preparing such compositions are also provided. The compositions may be used for the treatment of prostate cancer.